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Introduction {#sec1}
============

The airway epithelium of both mouse and humans is essentially quiescent at steady state, with an extremely low rate of stem cell proliferation ([@bib6], [@bib22], [@bib45]). Nevertheless, airway basal cells (BCs) can rapidly enter the cell cycle in response to luminal cell loss ([@bib20], [@bib33], [@bib37]). Several paracrine signaling pathways that promote airway stem cell proliferation following injury have been characterized (reviewed in [@bib18]). In addition, autocrine signaling mechanisms can initiate airway proliferation in response to local damage ([@bib46]). A critical question remains: are there are also mechanisms which actively inhibit airway proliferation at homeostasis and therefore function to maintain quiescence?

In overall organization the mouse trachea is very similar to human smaller airways ([@bib16], [@bib40], [@bib45]). The adult mouse tracheal epithelium comprises three main cell types. BCs include both slowly dividing stem cells and committed luminal precursors ([@bib30], [@bib39], [@bib50]). Luminal secretory cells can self-renew and produce luminal ciliated cells, while ciliated cells are terminally differentiated ([@bib36], [@bib37], [@bib38]). In vitro and in vivo evidence suggests that airway BC proliferation requires epidermal growth factor receptor (EGFR) activity ([@bib4], [@bib55]). Moreover, inhibition of EGFR signaling via contact inhibition is necessary to restrain BC proliferation following injury ([@bib27]). WNT and Notch signaling can also promote BC proliferation in some contexts ([@bib14], [@bib34], [@bib41]). By contrast, YAP prevents differentiation of BCs ([@bib28], [@bib56]). However, no specific signaling pathways that actively inhibit BC proliferation at steady state have been identified.

In other organs, stem cell quiescence is actively maintained by feedback inhibition. For example, in the satellite cells of skeletal muscle steady-state quiescence requires the function of specific receptor tyrosine kinase (RTK) inhibitors, SPRY proteins, to antagonize pro-proliferative fibroblast growth factor receptor 1 (FGFR1) signaling ([@bib5], [@bib43]). We speculated that similar mechanisms would operate in the steady-state airway epithelium.

FGFR signaling has been extensively studied in lung development and the smaller conducting airways (e.g., [@bib1], [@bib47], [@bib48], [@bib54]) where, similar to its role in muscle, it has been found to have a pro-proliferative function. However, the role of FGFR signaling in airway BCs remains undetermined. We therefore tested whether antagonism of FGFR1 activity by SPRY proteins is required for BC quiescence. Surprisingly, we found that deletion of either *Fgfr1* or *Spry2* resulted in increased levels of BC proliferation. We demonstrate that in airway BCs, SPRY2 is post-translationally modified downstream of FGFR1, allowing SPRY2 to antagonize signaling from other RTKs, most likely EGFR, and maintain quiescence. There is a well-documented in vitro relationship between FGFR1-mediated modification of SPRY2 and RAS-ERK inhibition ([@bib25], [@bib26]). However, a role for this interaction has never previously been identified in vivo.

Results {#sec2}
=======

FGFR1 Signaling Is Required for Normal Tracheal Cellular Homeostasis {#sec2.1}
--------------------------------------------------------------------

FGFR signaling pathway components are readily detected in the steady-state adult mouse trachea by RT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}A). *Fgfr1* and *Spry2* mRNA were also detected in purified BC, secretory, and ciliated cell populations by qRT-PCR ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C) and by single-cell qRT-PCR ([@bib50]). Moreover, FGFR1 protein and mRNA were detected in BCs and luminal cells in the intact mouse trachea ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1F). We conditionally deleted *Fgfr1* and activated a GFP reporter in tracheal BCs using *Tg*(*KRT5-CreER*); *Rosa26R-fGFP*; *Fgfr1*^*Δ/fx*^ (*Fgfr1* conditional knockout, cKO) and control *Tg*(*KRT5-CreER*); *Rosa26R-fGFP* mice. Four doses of tamoxifen (tmx) were administered to adult (\>8 weeks old) mice ([Figure 1](#fig1){ref-type="fig"}B). To confirm deletion of *Fgfr1*^*fx*^ in the GFP^+^ BCs, we performed qRT-PCR on pools of isolated GFP^+^ BCs and showed that the level of *Fgfr1* mRNA in the *Fgfr1* cKOs was reduced to 20% of the control level ([Figure 1](#fig1){ref-type="fig"}C). This result showed that widespread co-recombination of the *Fgfr1*^*fx*^ and *Rosa26R*^*fGFP*^ loci was occurring, and we used GFP^+^ cells as a surrogate marker for *Fgfr1*^*Δ/Δ*^ cells in further experiments. However, it is important to note that *Rosa* and *Fgfr1* co-recombination is ∼80%, and we therefore underestimate the extent of the *Fgfr1* phenotype using this scoring method.

Tracheae were harvested at intervals and processed for histology to assess the contribution of GFP^+^, *Fgfr1*^*Δ/Δ*^ BCs to the epithelium during normal homeostatic turnover. At 1.5 weeks after tmx administration, ∼30% of total BCs were GFP^+^ in both *Fgfr1* cKOs and controls. In control animals this percentage increased modestly to 40%--50% at 5--13 weeks after tmx administration, before dropping to initial levels by 24 weeks. This change was much more marked in the *Fgfr1* cKO mice, in which the percentage of labeled BCs peaked at 60% at 13 weeks before returning to initial levels ([Figures 1](#fig1){ref-type="fig"}D and 1E). In both genotypes, labeled BCs produced labeled luminal cells as expected. However, luminal cell production was greater in the *Fgfr1* cKO mice, with levels of GFP^+^ luminal cells reaching 38% ± 2% of the total luminal cell population by 24 weeks, compared with 21% ± 4% in the controls ([Figure 1](#fig1){ref-type="fig"}F). *Tg*(*KRT5-CreER*); *Rosa26R-fGFP*; *Fgfr1*^*+/fx*^ (*Fgfr1* conditional heterozygous) mice displayed a phenotype similar to that of the cKOs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Thus, greater numbers of both basal and luminal cells are produced by the *Fgfr1*^*Δ/Δ*^ BCs than controls, showing that FGFR1 signaling influences the rate of epithelial cell turnover in the steady-state trachea.

Increased Levels of Basal Cell Proliferation in the *Fgfr1* cKO Tracheae {#sec2.2}
------------------------------------------------------------------------

We assessed proliferation rates using KI67 antibody staining. This showed that in vivo rates of proliferation were \>3-fold higher in the *Fgfr1*^*Δ/Δ*^ BCs than in controls ([Figures 2](#fig2){ref-type="fig"}A and 2B). Moreover, the level of *Ki67* mRNA in GFP^+^ BCs isolated from *Fgfr1* cKO tracheae was increased 11-fold compared with controls ([Figure 2](#fig2){ref-type="fig"}C). Proliferation levels were intermediate in the *Fgfr1* conditional heterozygotes ([Figure S2](#mmc1){ref-type="supplementary-material"}C). We confirmed the increase in BC proliferation in vitro using a limiting dose of Cre recombinase adenovirus (Ad-Cre) to induce recombination in small numbers of cells from *Rosa26R-fGFP*; *Fgfr1*^*Δ/fx*^ and control *Rosa26R-fGFP* tracheae ([Figure 2](#fig2){ref-type="fig"}D). The *Fgfr1*^*Δ/Δ*^ cells produced larger GFP^+^ colonies than the controls, and these cultures also contained higher numbers of KI67^+^ cells ([Figures 2](#fig2){ref-type="fig"}E--2G).

We predicted that if deletion of *Fgfr1* results in BC proliferation, activating FGFR1 signaling in vitro would inhibit growth of BC colonies. FGF2 is expressed in the homeostatic trachea ([Figure S1](#mmc1){ref-type="supplementary-material"}A), is known to activate FGFR1 preferentially in vitro, and is strongly linked to FGFR1 activation in multiple in vivo situations ([@bib2], [@bib5], [@bib13], [@bib16], [@bib17], [@bib24], [@bib32]). We therefore tested the effects of the addition of exogenous FGF2 protein on the proliferation of wild-type primary BCs in culture. We plated wild-type BCs at low density and added FGF2 on culture day 2 after colonies had become established ([Figure 2](#fig2){ref-type="fig"}H). As predicted, addition of FGF2 had the opposite effect to removal of *Fgfr1* and significantly reduced colony size ([Figures 2](#fig2){ref-type="fig"}I and 2J).

*Fgfr1*^*Δ/Δ*^ BCs Have Increased Levels of MAPK and AKT Pathway Activity {#sec2.3}
-------------------------------------------------------------------------

To identify the mechanism by which FGFR1 influences BC proliferation, we assessed the levels of activity of well-characterized downstream intracellular signaling pathways. Given that we had successfully replicated the proliferation phenotype in primary cell culture ([Figures 2](#fig2){ref-type="fig"}D--2F), we used primary cultures of *Fgfr1*^*Δ/fx*^ cells with a high dose of Ad-Cre and harvested cells 3 days after infection for western analysis of the whole cell lysate ([Figure 3](#fig3){ref-type="fig"}A). Genotyping of the cultures suggested that many cells were *Fgfr1*^*Δ/Δ*^ in these conditions ([Figure S3](#mmc1){ref-type="supplementary-material"}A). These experiments showed that there was a 2.2-fold increase in levels of phosphorylated ERK1/2 in the *Fgfr1*^*Δ/Δ*^ cells. In addition, there was a 3.8-fold increase in total AKT protein and a 1.3-fold increase in the fraction of phosphorylated AKT ([Figures 3](#fig3){ref-type="fig"}B and 3C). The change in MAPK pathway activity was confirmed in vivo by immunostaining for pERK1/2, which showed higher levels in *Fgfr1*^*Δ/Δ*^ BCs than controls at 1.5 weeks after tmx administration ([Figure 3](#fig3){ref-type="fig"}E). Thus, the loss of an RTK surprisingly resulted in increased levels of signaling through the RAS-ERK and PI3K intracellular pathways, which are typically associated with active RTK signaling. We therefore analyzed negative regulators of these signaling cascades. SPRY2 is a well-known transcriptional target of FGFR signaling and has previously been shown to be post-translationally modified downstream of FGFR1 activity in vitro ([@bib26], [@bib42]). Two isoforms of SPRY2 can be separated on polyacrylamide gels. Levels of the faster-migrating (lower) isoform have been shown in vitro to increase following FGFR1 activation. In addition, this isoform has a greater ability to bind to GRB2 in vitro and has been proposed to be the active isoform for inhibition of RAS-ERK signaling ([@bib26]). Interestingly, in the *Fgfr1*^*Δ/Δ*^ cells there was a 2.2-fold decrease in levels of the faster-migrating (lower, active for ERK/AKT inhibition) SPRY2 isoform and a 1.3-fold increase in levels of the slower-migrating (upper, unable to inhibit ERK/AKT) isoform ([Figures 3](#fig3){ref-type="fig"}B and 3C). This suggests that a wild-type function of FGFR1 signaling in the tracheal BCs is to modulate SPRY2 activity post-translationally, thus altering the ability of SPRY2 to inhibit signaling downstream of other RTKs ([Figure 3](#fig3){ref-type="fig"}D).

There is a strong connection between EGFR signaling and airway BC proliferation ([@bib4]). We tested the hypothesis that because the *Fgfr1* cKO BCs have more constitutive activity of the ERK/AKT pathways, they would be more resistant to EGFR inhibition than controls. We grew *Fgfr1* cKO and control BCs in the presence of 0.25 μM of the EGFR inhibitor erlotinib ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This resulted in a \>5-fold decrease in proliferation rates in the control cells, versus a 2-fold decrease in the *Fgfr1* cKO cells ([Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D). Moreover, levels of EGFR protein were unchanged in the *Fgfr1* cKO cells ([Figure S4](#mmc1){ref-type="supplementary-material"}E). The *Fgfr1* cKO BCs are thus more resistant to EGFR inhibition, supporting the hypothesis that the downstream signaling pathways (ERK/PI3K) are more constitutively active in these cells.

Stimulating BCs with FGF2 Results in Increased Levels of the Faster-Migrating SPRY2 Isoform {#sec2.4}
-------------------------------------------------------------------------------------------

We tested whether activating FGF signaling is sufficient to modulate levels of the SPRY2 isoforms in wild-type cells ([Figure 3](#fig3){ref-type="fig"}F). A 10-min or 24-hr FGF2 stimulation resulted in a reproducible small decrease in pERK1/2 compared with control cells, particularly at the 10-min harvest time ([Figures 3](#fig3){ref-type="fig"}G, 3H, and [S5](#mmc1){ref-type="supplementary-material"}A--S5C). Following FGF2 stimulation we observed no change in total SPRY2 levels but a 1.6-fold increase in levels of the faster-migrating SPRY2 isoform ([Figures 3](#fig3){ref-type="fig"}G and 3H). These changes never reached statistical significance. However, the experiments were performed in primary cells that have multiple inputs into the ERK pathway in the presence of serum and the data were reproducible, supporting our hypothesis that manipulating FGFR1 signaling results in post-translational changes in SPRY2.

*Fgfr1*^*Δ/Δ*^ BCs Cannot Produce Ciliated Cells {#sec2.5}
------------------------------------------------

It has previously been reported that FGFR1 signaling in zebrafish and *Xenopus* embryos can regulate cilia assembly and length ([@bib19], [@bib31]). We therefore examined ciliogenesis in the *Fgfr1* cKO tracheae. At 24 weeks after tmx administration, *Fgfr1* cKO tracheae had an excess of GFP^+^ secretory cells and fewer GFP^+^ ciliated cells than the controls ([Figures 4](#fig4){ref-type="fig"}A and 4B), suggesting that ciliated cell production was impaired in the mutant. Indeed, the only GFP^+^ ciliated cells that could be detected in the *Fgfr1* cKO trachea still retained FGFR1 protein ([Figures 4](#fig4){ref-type="fig"}A and 4C), indicating that they were derived from *Fgfr1*^*Δ/fx*^ cells, which had undergone partial recombination to activate the *Rosa* reporter but had not deleted the *Fgfr1*^*fx*^ allele. Based on scoring the percentage of luminal GFP^+^ cells that retained detectable FGFR1 protein in these samples, we were able to estimate the rate of co-recombination of the two floxed alleles as 84% ± 2% ([Figure 4](#fig4){ref-type="fig"}C), in good agreement with our qRT-PCR-based estimate ([Figure 1](#fig1){ref-type="fig"}C).

To assess the stage at which ciliated cell differentiation was blocked in the *Fgfr1* cKO cells, we stained tracheal sections for the transcription factor FOXJ1, which is expressed during ciliated cell differentiation and has a role in basal body anchoring ([@bib3], [@bib21]). In the *Fgfr1* cKO tracheae the number of GFP^+^, FOXJ1^+^ cells was significantly decreased, confirming an early block in ciliated cell differentiation ([Figures 4](#fig4){ref-type="fig"}B and 4D). These data suggest that in the *Fgfr1* cKO tracheae, luminal cell fate choice is disrupted and secretory cells are produced at the expense of ciliated cells. This phenotype is somewhat different to the published role for FGFR1 in controlling cilia length in multi-ciliated cells in the zebrafish and *Xenopus* systems ([@bib19], [@bib31]). This may be a true cross-species difference or may reflect the limitations of the different experimental systems used.

Homeostatic production of new ciliated cells occurs at an extremely slow rate in vivo ([@bib36]). To confirm the ciliated cell differentiation phenotype in the *Fgfr1*^*Δ/Δ*^ cells, we grew air-liquid interface (ALI) epithelial cultures from *Rosa26R-fGFP*; *Fgfr1*^*Δ/fx*^ and control *Rosa26R-fGFP*; *Fgfr1*^*+/fx*^ tracheae and deleted the floxed alleles using Ad-Cre ([Figure 4](#fig4){ref-type="fig"}E). All control cultures had robust differentiation of ciliated cells, based on acetylated tubulin (ACT) localization, but ciliated cells were not observed in the *Fgfr1* cKO cultures ([Figure 4](#fig4){ref-type="fig"}F).

In summary, the *Fgfr1* cKO BCs have an increased proliferation rate from 1.5 weeks after injection. They are also unable to produce mature ciliated cells, likely due to a fate-choice defect. We focused on BC proliferation as the primary phenotype and, based on our observation that levels of the fast-migrating SPRY2 isoform were decreased in the *Fgfr1* cKO cells ([Figures 3](#fig3){ref-type="fig"}B and 3C), we hypothesized that a major role of FGFR1 signaling in the tracheal BCs is to modulate SPRY2 activity and, moreover, that the function of SPRY2 in these cells is to inhibit signaling activity downstream of RTKs other than FGFR1, for example EGFR, which is necessary for tracheal BC proliferation ([@bib4], [@bib27]). To test this hypothesis, we deleted *Spry2* in BCs of the adult mouse trachea.

Loss of *Spry2* Results in Increased Levels of Tracheal Basal Cell Proliferation {#sec2.6}
--------------------------------------------------------------------------------

*Spry2* is widely expressed in basal and luminal cells of the homeostatic mouse trachea ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). We generated *Tg*(*KRT5-CreER*); *Rosa26R-fGFP*; *Spry2*^*Δ/fx*^ (*Spry2* cKO) and control *Tg*(*KRT5-CreER*); *Rosa26R-fGFP* adult mice and administered tmx to activate GFP and delete *Spry2* in a subset of BCs ([Figure 5](#fig5){ref-type="fig"}A). During normal turnover there was an increase in the proportion of GFP^+^, *Spry2*^*Δ/Δ*^ BCs compared with GFP^+^, *Spry2*^*+/+*^ controls ([Figures 5](#fig5){ref-type="fig"}B and 5C). At the same time the proportion of GFP^+^, *Spry2*^*Δ/Δ*^ luminal cells also increased ([Figures 5](#fig5){ref-type="fig"}B and 5D). These changes most likely resulted from the ∼4-fold increase in rates of BC proliferation observed in the *Spry2* cKOs compared with controls ([Figures 5](#fig5){ref-type="fig"}E and 5F). The proliferation phenotypes were thus very similar between the *Fgfr1* and *Spry2* cKO tracheae, supporting a strong connection between the two proteins. However, unlike the *Fgfr1* cKO, no effects on ciliated cell differentiation were observed in the *Spry2* cKO tracheae ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), suggesting that the function of FGFR1 in luminal fate choice is SPRY2 independent. In addition, in contrast to *Fgfr1*, no phenotypes were observed in *Spry2* conditional heterozygous tracheae (data not shown).

The *Spry2* cKO cells were packed more tightly than control cells in the epithelium (at 13 weeks after tmx administration there were 16 ± 1.3 cells per 40 μm in the control tracheal epithelia versus 23.7 ± 1.6 cells per 40 μm in the *Spry2* cKOs; p = 0.01; [Figure 5](#fig5){ref-type="fig"}B), consistent with the significantly increased proliferation rate. However, there was no evidence of epithelial stratification, and levels of E-cadherin protein ([Figure 5](#fig5){ref-type="fig"}G) and apical-basal polarity ([Figure S6](#mmc1){ref-type="supplementary-material"}C) appeared normal. These data suggest that the observed change in cell density may result from an altered threshold for contact inhibition in the *Spry2* cKO cells.

We tested whether we could recapitulate the *Spry2* cKO phenotypes using Ad-Cre in primary tracheal cell culture ([Figure 6](#fig6){ref-type="fig"}A). Deletion with a high titer of Ad-Cre resulted in loss of all detectable SPRY2 protein ([Figure 6](#fig6){ref-type="fig"}E) and failure to amplify the *Spry2*^*fx*^ allele from the genomic DNA ([Figure S3](#mmc1){ref-type="supplementary-material"}B), suggesting that we achieved complete recombination of the *Spry2*^*fx*^ allele. In spite of this there were large patches of GFP^−^ cells in our cultures that had not recombined the *Rosa* reporter ([Figure 6](#fig6){ref-type="fig"}B). This indicates that the *Spry2*^*fx*^ allele recombines more efficiently than the *Rosa26R-fGFP* reporter and supports the conclusion that most of the GFP^+^ cells observed in vivo were co-recombinants with *Spry2*^*fx*^. Therefore, it is likely that scoring GFP^+^ cells in the *Spry2* cKO tracheae results in a good approximation to the *Spry2*^*Δ/Δ*^ phenotype (compare with the *Fgfr1* cKO tracheae, where scoring GFP^+^ cells results in an underestimate of the *Fgfr1*^*Δ/Δ*^ phenotype).

The *Spry2*^*Δ/Δ*^ cultures had a greater rate of proliferation than the controls and also reached a higher cell density ([Figures 6](#fig6){ref-type="fig"}B and 6C). Proliferation of the *Spry2*^*Δ/Δ*^ cells slowed after the cells reached confluence, but did continue ([Figure 6](#fig6){ref-type="fig"}C). Moreover, confluent cultures could easily be passaged and continued to show a faster proliferation rate ([Figure 6](#fig6){ref-type="fig"}D). Importantly, although the *Spry2*^*Δ/Δ*^ cells reached a greater density than controls, we never observed phenotypes consistent with a complete loss of contact inhibition, such as multi-layering or cell detachment. This is again consistent with an altered threshold for, but not complete loss of, contact inhibition.

Similar to the *Fgfr1*^*Δ/Δ*^ cells, the *Spry2*^*Δ/Δ*^ cells had a 3.5-fold increase in pERK1/2 and a 5.2-fold increase in pAKT levels compared with the controls ([Figures 6](#fig6){ref-type="fig"}E and 6F). These changes were highly reproducible, although not always statistically significant. The increase in MAPK pathway activity was confirmed in vivo by immunostaining for pERK1/2, which showed higher levels in *Spry2*^*Δ/Δ*^ BCs than controls at 1.5 weeks after tmx administration ([Figure 6](#fig6){ref-type="fig"}G). We also observed that the *Spry2*^*Δ/Δ*^ cells had a 3.3-fold increase in levels of EGFR protein ([Figures 6](#fig6){ref-type="fig"}E and 6F). This is consistent with the published function of the slower-migrating SPRY2 isoform (which is absent in the *Spry2*^*Δ/Δ*^ cells, but is unaffected in the *Fgfr1*^*Δ/Δ*^ cells) in EGFR trafficking/degradation ([@bib12], [@bib23], [@bib49]).

Discussion {#sec3}
==========

The tracheal epithelium is normally quiescent, with a minimal amount of cell turnover. By combining in vivo genetic analysis and primary cell culture, we have shown that BC proliferation is actively repressed under steady-state conditions by an FGFR1-SPRY2 signaling axis that functions to inhibit signaling through the ERK and AKT intracellular pathways. This result argues that airway quiescence does not result simply from the absence of a proliferative signal or from feedback inhibitory loops. Rather, we propose a model in which quiescence is maintained by a balance between signaling mechanisms that either promote proliferation or repress it. This is an emerging theme in the stem cell biology of quiescent organs. For example, a recent publication has found a similar tonic Hedgehog signal that inhibits steady-state proliferation in the smaller mouse airways ([@bib35]), but it is not known whether this Hedgehog-based mechanism applies in the BC-containing trachea.

SPRY2 was previously characterized in vitro as a protein with two isoforms, which can either inhibit ERK/AKT signaling (faster-migrating SPRY2 isoform) or modulate the subcellular trafficking/degradation of EGFR protein (slower-migrating isoform) ([@bib15]). However, the relative roles of these SPRY2 isoforms in vivo and how they function downstream of RTK receptors have not previously been explored. Several lines of evidence presented here support a model in which the faster-migrating SPRY2 functions downstream of FGFR1 to control cell proliferation and tracheal epithelial homeostasis ([Figure 7](#fig7){ref-type="fig"}A). First, following the loss of FGFR1 protein in airway BCs we observe reduced levels of the faster-migrating (ERK/AKT-inhibiting) SPRY2 isoform, as well as increased levels of dpERK and pAKT, increased rates of proliferation, and increased resistance to EGFR inhibition. By contrast, the slower-migrating SPRY2 isoform is unaffected ([Figure 7](#fig7){ref-type="fig"}B). Second, exposing wild-type BCs to FGF2 ligand results in increased levels of faster-migrating SPRY2, a decrease in dpERK, and inhibition of BC proliferation. Third, loss of all SPRY2 results in increased ERK/AKT signaling and BC proliferation ([Figure 7](#fig7){ref-type="fig"}C). Taken together, our data suggest that active FGFR1 signaling in the steady-state trachea maintains a pool of SPRY2 protein, which functions to antagonize ERK/AKT signaling and limit cell proliferation downstream of other RTKs, most likely EGFR ([Figure 7](#fig7){ref-type="fig"}A). A relationship between FGFR1 and post-translational modification of SPRY2 protein has previously been documented in cell lines in vitro ([@bib25], [@bib26]). We now demonstrate its importance in vivo, clearly illustrating that the context in which a cell interprets EGFR/RTK signaling can be highly dependent on the activity of other RTKs present. This has clear implications for cancer development and the evolution of drug-resistant tumors.

Another important finding of our work is that FGFR1 and SPRY2 can also function independently in airway epithelial homeostasis. FGFR1 is required for multi-ciliated cell differentiation ([Figure 4](#fig4){ref-type="fig"}). Moreover, our data suggest that secretory cells are produced at the expense of ciliated cells by the *Fgfr1* cKO BCs. A role for FGFR1 in ciliated cell differentiation is also consistent with previous reports from other model organisms ([@bib19], [@bib31]), but the details of the cellular requirements remain to be worked out. SPRY2 regulates EGFR protein levels in BCs ([Figure 6](#fig6){ref-type="fig"}). Similar observations have previously been made in vitro or in cancer models, but we demonstrate this SPRY2-EGFR relationship for the first time in a homeostatic tissue ([@bib12], [@bib23], [@bib49]). SPRY2 thus emerges as a highly flexible switch that can be modulated by FGFR1 signaling to control different aspects of RTK signaling. In excess of ten phosphorylation sites and multiple binding partners have been documented for SPRY2 in vitro ([@bib8], [@bib11], [@bib26]). These data suggest that SPRY2 is extensively and flexibly modified in many different cellular settings in vivo and that our observations may be the tip of the iceberg for the control of cellular homeostasis by SPRY2.

A key question raised by our model concerns what activates FGFR1 in vivo. We observed that FGF2 is transcribed in the tracheal mesenchyme in vivo at steady state, and that recombinant FGF2 inhibits tracheal BC proliferation and modulates SPRY2 in vitro. These data are consistent with a role for FGF2 in activating FGFR1 signaling in vivo, although we note that other FGF ligands are expressed in the steady-state airways. Interestingly, in a recent screen of secreted proteins for their effect on the ability of human airway BCs to form clonal organoids in culture, addition of FGF2 resulted in smaller tracheospheres with fewer BCs ([@bib7]). This is highly consistent with our in vitro results and suggests that a role for FGF2 signaling in inhibiting airway BC proliferation is conserved between mouse and humans.

Amplification of the *FGFR1* locus, or increased levels of FGFR1 protein, have been observed in 10%--20% of squamous lung cancer cell lines, where FGFR1 has been implicated as a driver mutation and putative therapeutic target ([@bib10], [@bib51], [@bib52]). How do we reconcile this increase in FGFR1 expression in airway cancer with our finding that an FGFR1-SPRY2 signaling module is required to limit mouse airway BC proliferation at steady state? This will clearly require future investigation. However, the squamous cell cancer lines used in these studies were isolated from the end stage of a cancer development process and have undergone many genetic and epigenetic changes. Given the highly context-dependent and cell-type-specific nature of FGFR1 signaling, and its interaction with SPRY2 and other RTKs as we have observed, its function may change drastically during neoplasia development. Nevertheless, we note that if a normal function of FGFR1 signaling is to inhibit proliferation of wild-type airway BCs, then it is possible that administration of FGFR1-specific inhibitors as a cancer therapy may lead to clonal expansion of other pre-malignant cells.

In conclusion, airway epithelial quiescence requires active inhibition of proliferation by FGFR1 signaling, which results in the post-translational modification of SPRY2 and inhibition of signaling downstream of other RTKs, partly EGFR. We have thus demonstrated a specific in vivo function for an FGFR1-SPRY2 signaling axis that was previously documented in vitro. This illustrates the complexity of RTK signaling networks and the importance of further investigation in both homeostatic tissues and developing malignancies.

Experimental Procedures {#sec4}
=======================

See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for a full description of all materials and methods used.

Mice {#sec4.1}
----

Experiments were performed under Home Office licenses PPL80/2326 and 70/812. *Fgfr1*^*fx*^ ([@bib53]), *Tg*(*KRT5-CreER*) ([@bib39]), *Rosa26R-fGFP* ([@bib38]), *Spry2*^*fx*^ ([@bib44]) were described previously. *Fgfr1*^*Δ/+*^ and *Spry2*^*Δ/+*^ were generated by crossing floxed alleles to *Zp3-Cre* ([@bib9]). All strains were maintained on a C57Bl/6J background. Males and females \>8 weeks old were used. Wild-type mice were C57Bl/6J.

Tamoxifen {#sec4.2}
---------

Animals were injected intraperitoneally with tmx, 0.2 mg/g body weight, four times every other day.

Tracheal Epithelial Cell Culture {#sec4.3}
--------------------------------

Tracheae were cut into small pieces and incubated in 50% Dispase II (Gibco, 16 U/ml). Epithelial sheets were isolated and dissociated to single cells. Unless otherwise stated, 5 × 10^4^ cells in 0.5 ml of MTEC/+ medium ([@bib55]) were plated on collagen-coated 12-well tissue culture inserts (BD Falcon, 353180). Differentiation was induced in confluent cultures by removal of insert medium and addition of MTEC serum-free medium to the outer chamber. Ad-Cre (University of Iowa, Gene Transfer Vector Core) MOI 7 was used for scattered recombination and MOI 2,500 for complete recombination; 1 × 10^6^ vector plaque-forming units, 100 ng/ml recombinant mouse FGF2, and 0.25 μM erlotinib (Sigma).

Immunostaining {#sec4.4}
--------------

Cryosections (6 μm) or whole-mount primary cultures were stained with ACT (mouse, 1:3,000, Sigma, T7451), E-cadherin (rat, 1:3,000, Invitrogen, 13-1900), pERK1/2 (rabbit, 1:200, Cell Signaling Technology, 4695), FGFR1 (rabbit, 1:200, Novus Biologicals, NBP1-20067), FOXJ1 (mouse, 1:200, eBioscience, clone 2A5, 14-9965-80), GFP (chick, 1:1,000, Abcam, Ab13970), KRT5 (rabbit, 1:500, Covance, PRB-160P), KI67 (mouse, 1:200, Becton Dickinson, 550609), SCGB1A1 (goat, 1:400, Santa Cruz Biotechnology, sc9772), SPRY2 (rabbit, 1:200, Abcam, Ab50317), and T1α (1:1,000, DSHB, 8.1.1). Antigen retrieval was in 10 mM boiling sodium citrate for KI67 (pH 8), pERK1/2 (pH 6.5), and FOXJ1 (pH 6). Conjugated secondary antibodies were Phalloidin-568 and Alexa Fluor (Life Technologies, 1:2,000).

mRNA In Situ Hybridization {#sec4.5}
--------------------------

Cryosections (10 μm) were hybridized with DIG-labeled anti-sense mRNA probes to *Fgfr1* (EST: AW495528) or *Spry2* ([@bib29]) (DIG RNA labeling kit, Roche, 11175025910), and visualized using alkaline phosphatase-coupled anti-DIG (1:2,000, Roche, 12930023) and BCIP/NBT (Roche, 1383213).

Microscopy and Image Scoring {#sec4.6}
----------------------------

Slides were imaged on a Zeiss AxioImager compound microscope or a Leica Sp8/Sp5 confocal microscope as stated. Cells were scored manually in Fiji (ImageJ), or using the Gurdon Institute Imaging Facility\'s plugin ObjectScan. For cryosections, every epithelial cell along the entire proximal to distal length of a longitudinal section from the center of the trachea was scored. BCs were T1α^+^ or KRT5^+^ with the apical surface not reaching the lumen. For cultured cells, at least three random fields of view per insert were scored.

RT-PCR {#sec4.7}
------

Samples were enriched for epithelium or mesenchyme using Dispase digestion and manual peeling. Total RNA was extracted using TRIzol reagent.

qRT-PCR {#sec4.8}
-------

Primary tracheal epithelial cells were isolated and sorted using a fluorescence-activated cell sorting MoFlo flow cytometer. Wild-type cells were gated as basal EpCAM, GSIβ4 lectin; secretory EpCAM, SSEA1; and ciliated EpCAM, CD24. GFP^+^ BCs from control and *Fgfr1* cKO tracheae were sorted as GFP, GSIβ4 lectin. Total RNA was extracted using a Qiagen RNEasy Mini Kit, and Taqman gene expression assays (Life Technologies) were used.

Immunoblots {#sec4.9}
-----------

Cells were collected in Cell Extraction Buffer (Invitrogen, FNN0011) with protease inhibitor (Roche, 04693116001) and PMSF (Sigma, P7626). Proteins were separated on 10% or 12% SDS-PAGE gels before transfer to Millipore Immobilon-P PVDF Membrane (Merck Millipore, IPVH00010). Membranes were probed with pAKT(S473) (Cell Signaling, 3787, 1:3,000), pan-AKT (Cell Signaling, 4691, 1:1,000), dpERK1/2 (Cell Signaling, 4370, 1:300), ERK1/2 (Cell Signaling, 4695, 1:300), SPRY2 (Abcam, Ab50317, 1:300), SOX2 (Abcam, Ab97959, 1:3,000), Histone H3 (Abcam, Ab39655, 1:10,000), and EGFR (Millipore, 04-290, 1:300). Detection was performed with horseradish peroxidase-conjugated secondaries (Abcam, ab97051, ab97023, 1:10,000) and enhanced chemiluminescence (Thermo Scientific, PI-32109). Quantitation is based on analysis of protein from three biological replicates separated on the same polyacrylamide gel. Band intensity was analyzed in Fiji normalized to loading control.

Statistics {#sec4.10}
----------

Statistics were calculated using Student\'s two-tailed t test with unequal variance.
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![Deletion of *Fgfr1* in BCs Results in Altered Tracheal Epithelial Homeostasis\
(A) Relative expression of *Fgfr1* and *Spry2* mRNA in sorted wild-type basal, secretory, and ciliated cells.\
(B) Schematic of *Fgfr1* conditional knockout experiment.\
(C) Relative expression of *Fgfr1* mRNA in sorted GFP^+^ BCs from control and *Fgfr1* cKO mice 3 weeks after tmx administration.\
(D) Representative confocal sections from control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ tracheae. Green, GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei). Increased labeling of luminal cells is visible in the *Fgfr1* cKOs by 5 weeks (arrowheads), becoming large patches of labeled cells (brackets) by 13 and 24 weeks.\
(E) Percentage of the total T1α^+^ BCs that are also GFP^+^.\
(F) Percentage of total T1α^−^ luminal cells that are also GFP^+^.\
Error bars denote SEM. Scale bars, 50 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Loss of FGFR1 Signaling Results in Increased Levels of BC Proliferation\
(A) Representative confocal sections from control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ tracheae at 1.5 and 13 weeks after tmx administration. Green, GFP (reporter); red, KI67 (proliferating cells); white, KRT5 (BCs); blue, DAPI (nuclei). Arrowheads indicate KI67^+^ cells.\
(B) Percentage of GFP^+^ cells that co-express KI67.\
(C) Relative expression of *Ki67* mRNA in sorted GFP^+^ BCs from control and *Fgfr1* cKO mice 3 weeks after tmx administration.\
(D) Schematic of in vitro experiment.\
(E) Low-titer Ad-Cre infection induces sporadic recombination in control *Rosa26R*^*fGFP/+*^ and cKO *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ BCs. Green, GFP (reporter); blue, DAPI (nuclei).\
(F) *Fgfr1* deletion in vitro results in increased BC proliferation. Red, KI67 (proliferating cells); blue, DAPI (nuclei).\
(G) Percentage of proliferating (KI67^+^) cells in vitro.\
(H) Schematic for in vitro experiment. Wild-type (WT) BCs plated at low density (3 × 10^4^ cells/insert) and exposed to 100 ng/ml FGF2 from day 2.\
(I) FGF2-treated and control wild-type BCs at day 4 after plating. Red, E-cadherin (lateral cell membrane); blue, DAPI (nuclei).\
(J) Number of DAPI^+^ cells per colony in control and FGF2-treated cells.\
Error bars denote SEM, Scale bars represent 50 μm in (A), (E), and (F), and 20 μm in (I). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Loss of FGFR1 Signaling in BCs Leads to an Increase in Phosphorylation of Downstream Effector Proteins and a Decrease in Levels of a SPRY2 Isoform\
(A) Schematic of in vitro experiment.\
(B) Representative western blots from control and *Fgfr1* cKO day-5 BCs showing pERK1/2, total ERK1/2, pAKT, total AKT, SPRY2, and histone H3.\
(C) Quantification of protein in (B).\
(D) Model. A major function of FGFR1 in BCs is to post-translationally modify SPRY2, resulting in a SPRY2 isoform which can negatively regulate the ERK/MAPK and AKT/PI3K pathways downstream of other RTKs.\
(E) Confocal images of control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ tracheal sections at 1.5 weeks after tmx administration showing an increase in pERK1/2 levels in the *Fgfr1* cKO BCs. Green, GFP (reporter); red, pERK1/2 (active ERK1/2); blue, DAPI (nuclei). Scale bar, 25 μm.\
(F) Schematic for exposure of wild-type BCs to FGF2.\
(G) Representative western blots from day-6 FGF2-stimulated and control BCs showing SPRY2, pERK1/2, total ERK1/2, pAKT, total AKT, and histone H3.\
(H) Quantification of protein levels in (G).\
Error bars denote SEM. See also [Figures S3--S5](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Loss of FGFR1 Signaling Results in a Block in Ciliated Cell Differentiation\
(A) Confocal image of *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ tracheal section. Green, GFP (reporter); blue, FGFR1; red, SCGB1A1 (secretory cells); white, acetylated tubulin (ACT, cilia). In the patch of GFP^+^ cells marked by the dashed bracket, FGFR1 is absent and there are no ciliated cells. In the GFP^+^ cells within the solid bracket, FGFR1 has not been deleted, there are fewer GFP^+^ cells, and ciliated cell differentiation has occurred.\
(B) Percentage of GFP^+^ cells that co-express SCGB1A1, ACT, or FOXJ1 in control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*+/fx*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ animals 24 weeks after tmx administration.\
(C) Percentage of GFP^+^ luminal cells in cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Fgfr1*^*Δ/fx*^ trachea that retain FGFR1 protein 24 weeks after tmx administration.\
(D) Sections from control and *Fgfr1* cKO tracheae at 24 weeks after tmx administration. Green, GFP (reporter); red, γ-tubulin (basal bodies); white, FOXJ1 (ciliated cells).\
(E) Schematic of in vitro experiment.\
(F) Day-11 ALI cultures grown from control and *Fgfr1* cKO animals. Green, GFP (reporter); red, ACT (cilia); blue, DAPI (nuclei).\
Error bars denote SEM. Scale bars represent 100 μm in (A) and (F), and 50 μm in (D).](gr4){#fig4}

![Deletion of *Spry2* in BCs Results in Increased Rates of Proliferation\
(A) Schematic of *Spry2* conditional knockout experiment.\
(B) Representative confocal sections from control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Spry2*^*Δ/fx*^ tracheae. Green, GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei). Brackets indicate patches of labeled cells, more prominent in the *Spry2* cKO.\
(C) Percentage of the total T1α^+^ BCs that are also GFP^+^.\
(D) Percentage of the total T1α^−^ luminal cells that are also GFP^+^.\
(E) Representative confocal sections from control and cKO tracheae at 1.5 and 13 weeks after tmx administration. Green, GFP (reporter); red, KI67 (proliferating cells); white, KRT5 (BCs); blue, DAPI (nuclei). Arrowheads indicate KI67^+^ cells.\
(F) Percentage of GFP^+^ cells that co-express KI67.\
(G) Confocal z projections from sections of control and *Spry2 cKO* trachea. Green, GFP (reporter); red, KRT5 (BCs); white, E-cadherin (lateral cell membranes); blue, DAPI (nuclei).\
Error bars denote SEM. Scale bars represent 50 μm in (B) and (E), and 10 μm in (G). See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Rapidly Proliferating *Spry2* Conditional Knockout BCs Have Elevated Levels of RAS-ERK and PI3K Signaling\
(A) Schematic of in vitro experiment.\
(B) *Spry2* cKO (*Rosa26R*^*fGFP/+*^; *Spry2*^*Δ/fx*^) cells proliferate more rapidly than controls (*Rosa26R*^*fGFP/fGFP*^) in vitro and are more densely packed at culture day 5. Note that not all cKO cells are GFP^+^, even though SPRY2 protein is undetectable. Green, GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei). Arrowheads indicate similar regions of the cultures.\
(C) *Spry2* cKO cells still undergo some contact inhibition in vitro at day 7 after ALI induction. Their proliferation rate slows following induction of ALI and there are no regions of multi-layering, although KI67^+^ cells are still visible (arrowhead). Green, GFP (reporter); red, KI67 (proliferating cells); blue, DAPI (nuclei).\
(D) *Spry2* cKO primary cells continue to proliferate faster in vitro following passage at day 2 after replating. Green, GFP (reporter); red, KI67 (proliferating cells, e.g. arrowhead); blue, DAPI (nuclei).\
(E) Representative western blots from control and *Spry2* cKO day-5 BCs showing SPRY2, pAKT, total AKT, pERK1/2, total ERK1/2, SOX2, and histone H3.\
(F) Quantification of protein levels. Error bars denote SEM.\
(G) Confocal images of control *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^ and cKO *Tg*(*KRT5-CreER*); *Rosa26R*^*fGFP/+*^; *Spry*^*Δ/fx*^ tracheal sections at 1.5 weeks after tmx administration showing an increase in pERK1/2 levels in the *Spry2* cKO BCs. Green, GFP (reporter); red, pERK1/2 (active ERK1/2); blue, DAPI (nuclei).\
Scale bars, 25 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Model of the Roles of FGFR1 and SPRY2 in Airway Basal Cells\
(A--C) Model for FGFR1-SPRY2 function in airway BCs. (A) In wild-type BCs, FGFR1 signaling post-translationally modifies SPRY2 resulting in an isoform of SPRY2 (red), which is able to inhibit ERK/MAPK and AKT/PI3K signaling downstream of other RTKs, such as EGFR. This FGFR1-SPRY2 signaling axis limits BC proliferation, resulting in low levels of steady-state production of new cells. (B) Following loss of FGFR1 there is a much smaller pool of ERK/AKT-inhibiting SPRY2 (red) and, hence, more active ERK/MAPK and AKT/PI3K signaling and greater levels of BC proliferation and production of new basal and luminal cells. In addition, the *Fgfr1*^*Δ/Δ*^ cells cannot differentiate as mature multi-ciliated cells due to a role for FGFR1 signaling in luminal fate choice. (C) Similarly, following loss of all SPRY2 there is more active ERK/MAPK and AKT/PI3K signaling and greater levels of BC proliferation and, hence, production of new basal and luminal cells. Moreover, a second isoform of SPRY2 (orange), which may regulate the level of EGFR protein, is also lost. However, FGFR1 is present and ciliated cell differentiation is normal.](gr7){#fig7}
